Posted by Michael Wonder on 10 Nov 2021
KRPIA raises concern over HIRA’s cost effectiveness evaluation plan
10 November 2021 - Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over HIRA's plan of evaluating a drug’s cost effectiveness at 80% of the lowest drug price in Advanced 7 countries.
The HIRA’s plan was revealed when it replied to an inquiry by Rep. Kim Mi-ae of the People Power Party, who asked whether the Government planned to lower the price criteria in drug cost effectiveness evaluation.
